What is Sente?
Sente operates at the intersection of biotechnology and aesthetic dermatology, specializing in high-performance skincare products designed to mitigate complex skin concerns such as hyperpigmentation, redness, and chronic discoloration. Central to its value proposition is the proprietary HSA repair molecule, a patented innovation that distinguishes the brand from conventional over-the-counter alternatives. By focusing on dermatologist-approved formulations that bolster the skin's natural immune response, Sente has carved out a defensible market position. The company serves a sophisticated consumer base that prioritizes scientific efficacy and safety, particularly those with sensitive skin profiles requiring targeted, non-irritating therapeutic interventions.
How much funding has Sente raised?
Sente has raised a total of $1M across 1 funding round:
Debt
$1M
Debt (2020): $1M with participation from PPP
Key Investors in Sente
PPP
Public-Private Partnership
What's next for Sente?
With this major enterprise-level funding, Sente is poised to transition into a new phase of operational maturity. The strategic roadmap likely involves expanding its clinical trial pipeline to further validate the efficacy of its HSA technology across broader dermatological applications. Furthermore, the company is expected to enhance its omnichannel presence, potentially deepening its penetration into professional medical spas and clinical dermatology practices. As the medical-grade skincare market continues to consolidate, Sente's focus on evidence-based product development provides a strong foundation for sustained long-term growth and potential market leadership in the therapeutic skincare category.
See full Sente company page
